In this case, Mr. Chair, we pursued a number of different avenues in parallel.
Initially, it was the security branch of the health portfolio that conducted some initial fact-finding, for example, uncovering the patent in September 2018 that launched the subsequent investigations.
There are areas of the investigation that are administrative in nature. At the same time, our national security counterparts were notified and began their own parallel investigations. However, it is standard practice to ensure the independence of the investigation and full dedicated focus on it to contract with external agencies who have the required expertise to do so, but I would underline that this was in parallel to national security and law enforcement efforts.